Markets

Acorda Therapeutics (ACOR) Jumps: Stock Moves Up 12%

Acorda Therapeutics, Inc.ACOR was a big mover last session, as its shares rose roughly 12% on the day. The upside was driven by the company's announcement that it has reached a legal settlement with Actavis to resolve patent litigation related to its multiple sclerosis drug Ampyra. This also led to far more shares changing hands than in a normal session. Yesterday's rally breaks the trend for the company since Sep 21, as the stock is now trading above the volatile range of $25.78 to $30.80.

Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Acorda Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked biomedical stock is Anika Therapeutics Inc. ANIK with a Zacks Rank #1 (Strong Buy).

Is ACOR going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ACORDA THERAPT (ACOR): Free Stock Analysis Report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ANIK ACOR

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More